Advertisement

Topics

Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK

06:03 EDT 3 Oct 2017 | Lab Bulletin

The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio.GBP by the United Kingdom's innovation agency, Innovate UK.

themisThemis, the Vienna-based specialist for vaccine development, will use these funds to identify and validate a correlate of protection for its prophylactic Chikungunya vaccination candidate. Currently the candidate is tested in three parallel phase II clinical trials, including one that is performed in an endemic area for Chikungunya....

Original Article: Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK

NEXT ARTICLE

More From BioPortfolio on "Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK"

Quick Search
Advertisement